CINECA IRIS Institutional Research Information System

CAVALLA, Paola

CAVALLA, Paola  

NEUROSCIENZE "RITA LEVI MONTALCINI"  

Mostra records
Risultati 1 - 17 di 17 (tempo di esecuzione: 0.023 secondi).
Titolo Data di pubblicazione Autore(i) File
Cyclins and CDKs in classic and anaplastic oligodendroglioma 2003 Cavalla, P; Fiano, V; Schiffer, D.
Cyclins D1 and p27/Kip.1 in the differential diagnosis of diffuse astrocytomas and oligodendrogliomas 2002 Fiano, V.; Ghimenti, C.; Cavalla, P.; Schiffer, D.
Cyclins, CDKs and their inhibitor p27/Kip.1 in normal and neoplastic oligodendroglia 2002 Schiffer, D.; Fiano, V.; Ghimenti, C.; Cavalla, P.
F-box protein Skp2 is not the only pathway for p27/Kip.1 degradation 2002 Cavalla, P.; Fiano, V.; Ghimenti, C.; Mutani, R.; Schiffer, D.
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial 2014 Durelli, L.; De Mercanti, S.F.; Sormani, M.P.; Piazza, F.; Schiavetti, I.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D’Onghia, M.; Paolicelli, D.; Pinessi, L.; Trojano, M.; Clerico, M.
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study 2014 Clerico, M.; De Mercanti, S.; Piazza, F.; Virgilio, E.; Gned, D.; Brescia Morra, V.; Lanzillo, R.; Amato, L.; Quarantelli, M.; Ghezzi, A.; Bianchi, A.; Baroncini, D.; Salemi, G.; Realmuto, S.; Ferrò, M.T.; Vitetta, F.; Superti, G.; Cavalla, P.; D'Onghia, M.; Paolicelli, D.; Schiavetti, I.; Sormani, M.P.; Pinessi, L.; Trojano, M.; Durelli, L.
Neurodegeneration and iron accumulation in deep grey matter nuclei in multiple sclerosis. 2011 Vercellino M; Trebini C; Romagnolo A; Chiavazza C; Masera S; Mattioda A; Capello E; Mancardi G; Giobbe D; Mutani R; Giordana MT; Cavalla P
NEW INSIGHTS INTO THE ROLE OF MULTIPLE SCLEROSIS TREATMENT ON POLYMORPHONUCLEAR LEUKOCYTE FUNCTIONS AGAINST PATHOGENS 2016 Allizond, V; Scutera, S; Piersigilli, G; Musso, T; Cavalla, P; Trebini, C; Marra, Es; Tullio, V; Mandras, N; Roana, J; Cuffini, Am; Banche, G
p14ARF/Mdm2/p53 pathway deregulation in two glioblastoma series: with and without differentiated areas 2002 Ghimenti, C.; Fiano, V.; Chiadò-piat, L.; Cavalla, P.; Schiffer, D.
p27/Kip.1 ubiquitin ligase subunit skp2 relationships with cell proliferation and p27/Kip.1 expression in gliomas 2001 Schiffer, D.; Cavalla, P.; Fiano, V.; Vercellino, M.; Piva, R.; Pagano, M.
Relationship between apoptosis and caspase 3 expression in malignant gliomas 2001 Schiffer D.; Fiano V.; Ghimenti C.; Cavalla P.
Role of multiple sclerosis treatment on neutrophil multifaceted functions against bacteria. 2016 Allizond, V.; Scutera, S.; Piersigilli, G.; Musso, T.; Cavalla, P.; Trebini, C.; Marra, E.S.; Cristina, C.; Cuffini, A.M.; Banche, G
The phagocyte functional impairment in treated multiple sclerosis patients. 2015 ALLIZOND V.; SCUTERA S.; ROSSI S.; MUSSO T.; CAVALLA P.; TREBINI C.; CROCILLÀ C.; CUFFINI A.M.; BANCHE G.
The recognition of different pathways to apoptosis in gliomas migth have different biological significances 2001 Schiffer, D.; Fiano, V.; Ghimenti, C.; Cavalla, P.
The role of caspase-3 in the pathways to apoptosis in gliomas 2001 Fiano, V.; Ghimenti, C.; Cavalla, P.; Schiffer, D.
The uncertain definitions of oligodendrogliomas influence the evaluation of the efficacy of therapies 2001 Schiffer, D.; Cavalla, P.; Fiano, V.; Ghimenti, C.
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP 2014 Clerico, M; Schiavetti, I; De Mercanti, Sf; Piazza, F; Gned, D; Brescia Morra, V; Lanzillo, R; Ghezzi, A; Bianchi, A; Salemi, G; Realmuto, S; Sola, P; Vitetta, F; Cavalla, P; Superti, G; Ferraro, D; Paolicelli, D; Trojano, M; Sormani, Mp; Durelli, L